Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer-related Molecular Pathways, vaccines and immunoinformatics approaches, Ubiquitin and proteasome pathways, and Immunotherapy and Immune Responses.
Integrated epidemiological and molecular data inform the relationship between precancer and cancer states of esophageal adenocarcinoma
Towards canine immunotherapy models: Monoclonal antibodies with redox regulated epitopes targeting TIM3 attenuate Galectin-9 binding
Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Supplementary Table 2 from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides
Mass Spectrometry Advances in Analysis of Glioblastoma.
Supplementary Table 5 from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides
Supplementary Table 3 from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides
Data from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides
Supplementary legends from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides
DoggifAI: a transformer based approach for antibody caninisation
Supplementary notes from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides
Supplementary figures from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides
Supplementary Table 1 from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides
Supplementary Table 4 from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides
Disentangling oncogenic amplicons in esophageal adenocarcinoma
Novel FFPE proteomics method suggests prolactin induced protein as hormone induced cytoskeleton remodeling spatial biomarker
In Vitro Cross-Linking MS Reveals SMG1–UPF2–SMG7 Assembly as Molecular Partners within the NMD Surveillance
Supplementary Table 3 from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary Table 1 from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary Table 4 from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary figures from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary figures from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary Table 1 from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary notes from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary notes from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary Table 2 from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary Table 5 from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary legends from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Supplementary Table 2 from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides